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Abstract
Lymphadenectomy, for early stages of endometrial cancer (EC), provides a low
detection rate of lymphatic metastasis, without having demonstrated a therapeutic
effect; so that the collection and histological analysis of the sentinel lymph node
(SLN) might be an alternative to lymphadenectomy. The contribution of SLN to
surgical staging represents a change in the paradigm of lymphadenectomy in EC,
being an intermediate approach between not assessing the condition of the lymph
nodes and complete pelvic and paraaortic dissection. Accurate identification of the
main uterine drainage pathway increases the likelihood of detecting metastases
during lymphatic mapping. In addition, pathological assessment by the ultrastaging
of the SLN is the most important advance in the SLN biopsy (SLNB) technique. The
application of the SLNB presumes a decrease in surgical and long-term morbidity,
with an increase in the detection of lymphatic metastasis, mainly at the expense of
detecting low tumour volume, selecting the group of patients that would benefit
from a modification in adjuvant therapy. The SLNB can be established as an
oncologically safe and effective method in the surgical staging of early-stage EC.
Prospective studies are required to determine optimal behaviour and prognosis in
the detection of low-volume metastases.
Keywords: endometrial cancer, lymphatic mapping, predictive value of tests,
sentinel lymph node biopsy, ultrastaging
1. History and concept
The origins of lymphatic mapping date back more than 100 years, when Sappey
injected mercury into the skin of cadavers to delineate the skin’s lymphatic path-
ways [1, 2]. Lymphoscintigraphy was described by Shearman and Ter-Pogossian in
1953, both of whom confirmed Sappey’s hypothesis that lymphatic drainage occurs
in an orderly and predictable manner [2].
The origin of lymphatic drainage of tumours and its implications for surgical
staging are traced back to 1850 with the studies of Virchow and Haldsted on radical
axillary lymphadenectomy for breast cancer.
The contribution of SLN to surgical staging represents a change in the paradigm
of lymphadenectomy in EC. SLN represented an intermediate approach between
not assessing the condition of the lymph nodes and complete pelvic and paraaortic
dissection [3, 4]. The accurate identification of the main uterine drainage pathway
increases the likelihood of detecting metastases during lymphatic mapping [5].
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This information, provided by SLN, will change the therapeutic approach, with a
potential benefit in the prognosis, both in survival and quality of life [6].
2. Detection method
Theoretically, the ideal method for studying SLN in EC should meet the follow-
ing requirements:
1.Cause the least amount of patient discomfort possible, be easy to perform and
be reproducible.
2.Be a preoperative procedure that enables planning of the surgical approach
according to the anatomical location of the SLN.
3.Enable a laparoscopic approach according to the concept of minimally invasive
surgery.
4.Enable the detection of SLN without complete dissection of the retroperitoneal
space.
5.Obtain a lymphatic map representative of the tumour drainage or, at least, of
the uterine body drainage [7].
2.1 Lymphatic drainage of the uterus
Unlike superficial tumours, such as melanoma, the physiology of lymphatic
drainage in deeper/visceral tumours is not well established [8]. Uterine drainage, as
well as being bilateral, is therefore complex [9]. Anatomically, three segments of
uterine lymphatic drainage have been established:
1.The lower uterine segment drains from the paracervix to the parametrium and to
the broad ligament, passing by the obturator, internal iliac and interiliac lymph
node chains.
2.The middle third of the uterus drains the round ligament and the external iliac
lymph node chain.
3.The upper uterine segment drains through the infundibular pelvic ligament,
uterine-ovarian plexus and gonadal vessels towards the common iliac lymph
node chain, presacral lymph nodes and paraaortic lymph nodes [10].
Physiologically, there are two main lymphatic pathways and a third accessory
for uterine drainage [5]:
1.The main pathway or upper paracervical, located in the lymph trunks of the
parametrium. The lymphatic vessels of the uterine body often cross the
obliterated umbilical artery, which is the most common location of the pelvic
SLN, rising over the upper part of the obturator region, medial to the external
iliac vessels and ventral to the hypogastric vessels [5].
2.A less common pathway, the lower paracervical, is generally observed when
the lymphatic vessels do not cross the obliterated umbilical artery and move
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cranially over the course of the mesoureter. In these cases, SLN is usually
observed in the internal iliac, common iliac or presacral region.
3.A third pathway has been described, the infundibular pelvic, but it is very rare
except with fundal injections. This pathway has mainly fundal drainage
towards the broad ligament and paraaortic chain [11].
2.2 Injection techniques
Three main areas of injection on the uterus have been described: (1) corporal,
(2) endometrial and (3) cervical. Each area has been assessed with various
approaches: hysteroscopic, laparoscopic and ultrasound-guided transvaginal and
even with combined techniques.
1.Corporal: The injection can be subserosal or transmyometrial, in the anterior
wall, posterior wall or uterine fundus. Corporal injection by laparotomy, using
blue dye, was the first technique described. Subserosal injections have the
drawback of multiple injections [12] and anatomical distortion when dealing
with fibroids [13]. These injections might not be representative of the lesion if
the tumour does not infiltrate the uterine fundus. Due to the lack of
parametrial drainage, subserosal injections have a detection rate of 75–91% and
bilaterality of 80%, which is lower than that of cervical injections (p = 0.005)
[11], although the former has superior paraaortic drainage (31–40%) [14].
2.Endometrial: Intratumoural and peritumoural infiltration have superior
validity due to the proximity to the tumour lesion [10, 15]. The disadvantages
of this injection pathway are lower rates of bilaterality and paraaortic drainage,
which are determined by the location and size of the lesion [16]. Hysteroscopic
injections achieve detection rates of 69–80% [17, 18], with greater paraaortic
drainage (up to 60%) [15], without having shown superiority against other
injection pathways [19]. The hysteroscopic injection procedure is a more
complex and uncomfortable technique for the patient. Recent studies have
concluded that hysteroscopic injections do not have a correlation between the
location of the SLN and the location of the tumour in the uterine cavity [20].
The risk of tumour dissemination to the abdominal cavity has been shown to
be irrelevant [21]. Clamping the tubes before or after the injection of the dye
interferes with the detection rate by decreasing it [22].
In 2013, the group from the Hospital Clinic of Barcelona published their results
with the transvaginal ultrasound-guided myometrial injection of radiotracer
(TUMIR) technique, injecting 148 MBq of 99mTc-albumin nanocolloid (in a volume
of 8 mL) in the anterior and posterior peritumoural uterine wall, with migration of
90.5% and laparoscopic identification of 74.3%. The drainage was pelvic in 87.2%,
pelvic and paraaortic in 45.4% and exclusively paraaortic in 12.8% of cases.
Metastatic involvement of SLN in high-risk histology appeared in 24 patients, with
paraaortic extension in 30% of cases. The authors concluded that the TUMIR
technique is representative of tumour drainage and can be a promising detection
method in high-risk histology, although further studies on the technique are needed
[7]. The TUMIR technique has shown no differences compared with hysteroscopic
injections (p = 0.2) [7].
3.Cervical: The cervical injection is the modality most often reported in studies
[23]. The technique is reproducible, because the uterine cervix is accessible and
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rarely distorted in patients with EC [24]. The meta-analyses by Kang et al. [25]
and Bodurtha-Smith et al. [26] showed that hysteroscopic or subserosal
injections were associated with lower performance (p < 0.05), while cervical
administration was correlated with higher detection rates (92%; range, 62–100%
[27]; p = 0.031) [4] and bilaterality (56 vs. 33%; p = 0.003) (bilaterality is defined
as the detection of sentinel node on both sides of the pelvis). The disadvantage
was lower detection of paraaortic drainage (95% CI 3.4–10.1%) compared with
other techniques (7% cervical vs. 27% corporal; p = 0.001) [28–31].
In terms of the number of injections, there have been no differences between the
injection in two or four quadrants (with detection rates of 92 vs. 88%; p = 0.38), but
there is less dye dissemination if the injection is limited to two quadrants [31].
Geppert et al. [11] performed pericervical injections at 2, 4, 8 and 10 o’clock thereby
obtaining 5% paraaortic drainage. The MSKCC group recommended that cervical
injections in EC be bilateral (at 3 and 9 o’clock), both superficial (in the submucosa)
to 1–3 mm and deep (in the stroma) to 1–2 cm. In this way, the deep injection would
therefore arrive at the isthmus, ensuring parametrial drainage. Applying this tech-
nique, a threefold greater detection of lymphatic metastases is achieved (p = 0.045),
without assuming an increase in the overall detection rates (86%) [32]. The sys-
tematic review by Cormier et al. [27] determined that paraaortic detection has been
significantly greater with deep cervical infiltration (17 vs. 2%).
Taking into account the critical review of Frumovitz and Levenback [33] and
knowing the uterine drainage pathways, the location of the tumour will determine
the dissemination of the disease, and the injection technique might reflect the
pattern of lymphatic mapping. However, the study by Geppert et al. [11] concluded
that the cervical pathway (with submucosal and stromal injection) should be con-
sidered the standard pathway, not only due to being a safer injection technique but
also because the two main pathways of lymphatic drainage of the uterus were
identified regardless of the injection technique employed.
In terms of the lower cervical paraaortic drainage, numerous studies have veri-
fied that the incidence rate of paraaortic metastases isolated for EC in initial stages
is 5%, with approximately 50% of metastatic pelvic and paraaortic lymph nodes
[34]. Ninety percent of detected SLNs are located in the pelvic area; the rest are
presacral or paraaortic. The other techniques likely obtain greater paraaortic drain-
age, at the expense of underestimating the main pathway of pelvic drainage
[29, 30].
There is no known technique that detects with absolute bilaterality, and we still
do not know why a central organ, such as the uterus, has cases in which bilateral
drainage is not observed [20]. Ideally, the technique is considered valid if at least
one SLN is identified in each hemipelvis [11].
There is no one ideal or superior technique; all have shown good results, with
advantages and disadvantages [25]. Cervical injection is effective and reproduces
pelvic drainage. Corporal injection better reproduces paraaortic drainage and the
hysteroscopic pathway is representative of tumour drainage, although both are less
reproducible than the cervical pathway [4]. A number of authors have advocated
combined methods that provide better results. Studies such as the one by Holub
et al. [35] have combined cervical and subserosal injections, achieving detection
rates of 80%, without observing superiority over the two methods applied individ-
ually. In other studies with cervical and fundal injection, detection rates of 72.5%
were achieved, comparable results without superior paraaortic drainage (4.9 vs.
9.8%; p = 0.18) [6].
Table 1 shows a comparison of the main characteristics of the abovementioned
injection techniques.
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2.3 Sentinel node identification
Various tracers have been shown to be useful. The most commonly used tracers
in the lymphatic mapping of EC include 99mTc-nanocolloid, blue dyes and
indocyanine green (ICG), alone or in combination [36].
One inherent and necessary advantage of tracers is their high capacity for pene-
tration and fixation in lymphatic tissues [30]. The objective of lymphatic mapping
and preoperative marking with tracer is the ability to analyse at least one lymph
node per lymph node chain, two in the case of bilaterality [37].
SLNB was initially performed by the colorimetric method with methylene blue
(MB) or synthetic variants of blue dye. SLNB was later combined with the isotopic
detection of radiocolloids, thanks to the development of endoscopic gamma-ray
detection probes, becoming the standard for use. In recent years, the application of
lymphatic mapping by fluorescence in the near-infrared (NIR) electromagnetic
spectrum with ICG obviated the need for a nuclear medicine unit and avoiding the
adverse effects of blue dye, providing excellent results.
2.3.1 Preoperative marking: radiocolloid
The approach to studying the lymphatic pathways using nuclear medicine tech-
niques has gained considerable momentum in recent years with the development of
SLNB.
A radiopharmaceutical is a radioactive compound used for the diagnosis and
treatment of diseases. Radiopharmaceuticals’s property of transmitting radioiso-
topes for remote detection is employed to diagnostic purposes [38].
Radiopharmaceuticals can be classified, according to their chemical structure,
into primary radionuclides and labelled compounds, the latter of which are essen-
tially a combination of two components: a radionuclide and a particle. The particles
are small molecules, colloids, proteins and cells; the most widely used are colloidal
sulphur (USA) and albumin (Europe). The particle serves as a vehicle that selec-
tively directs the radiopharmaceutical to a specific tissue in response to physiolog-
ical conditions or specific patterns of gene expression [38]. The size of the particles
Characteristic Corporal Endometrial Cervical
Surgical approach for
injection:
Subserosal or transmyometrial by
laparoscopy or laparotomy
Hysteroscopy
Transvaginal
Ultrasound-guided
Transvaginal
Multiple injections ++ + 
Influence on anatomical
distortion or tumour size
++ + 
Increase in economic cost +/ + 
Technical complexity +/ + 
Reproducibility +  ++
Detection rate/bilaterality + ++ ++
Paraaortic drainage + ++ 
Comfort for the patient +/  +/
The score was assigned according to the following gradation: () = absence of the characteristic or negative evaluation,
(+) = meets the characteristic or positive evaluation, (++) = complies being better; (+++) = it fulfils being superior.
Table 1.
Characteristics of injection techniques.
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is important (range, 2–1500 nm) because it affects the drainage speed and retention
of particles in the lymph node [34].
The most widely used diagnostic radiopharmaceutical in nuclear medicine is
isomerised metastable 99mTc [38], which is nontoxic and has almost ideal physical
properties: a physical half-life to 99Tc (transition metal) of 6 h, a detectable emis-
sion and monochromatic gamma ray of 140 keV, complete disintegration within
24 h and low ionising radiation with negligible exposure [36, 39]. The greatest
contribution of radiopharmaceuticals is the ability to use it as a marker of distinct
pharmaceutical preparations, known as cold kits. The most used cold kit is the
Nanocoll® 500 μg/vial (GE Healthcare Bio-Sciences, S.A.U., Madrid), a compound
of colloidal particles of human serum albumin measuring ≤80 nm in diameter. The
compound therefore has avidity for absorption through the lymphatic capillaries,
and the size of its particles does not permit displacement of the lymph node.
To perform the SLNB, low doses of radioactivity are employed (40–185 MBq/
0.2–4 mCi) because the distribution space is highly reduced. Only the drainage to
the first or second lymph nodes needs to be assessed [38]. Furthermore, the injected
dose of radiocolloid is calculated based on the estimated time to surgery; the longer
the interval, the larger the dose to ensure an adequate signal. The 99mTc-albumin
nanocolloid is injected the day of the surgery (the radiocolloid injection is
performed 6 h before the operation with preoperative imaging 30 min after the
injection; the dose should be 0.2–1.0 mCi), a method known as the short protocol. If
the nanocolloid is injected the day before the surgery (at a dose of 2.0–4.0 mCi), the
method is known as the long protocol [40]. Therefore, the radioisotope compound
deposited in the interstitial space near the tumour will migrate to the lymphatic
capillaries until it reaches the first lymph node encountered by the capillaries. Due
to the size of the compound, the capillaries will be trapped, indicating the first
sentinel node into which the administered site drains. Moreover, both the short
half-life and the low injected dose leave relatively little space for flexibility in
surgical scheduling, given that hours-long delays and postponing the operation to
the following day due to logistics will compromise the efficacy of the lymphatic
mapping [36].
The compound is contraindicated when faced with hypersensitivity to the active
ingredient or any of the excipients and during pregnancy. As the radiocolloid is
primarily cleared by the kidneys but also by the hepatobiliary system, dose adjust-
ment is required for patients with renal and/or hepatic failure [39]. There have been
no reported adverse effects related to the radiopharmaceutical 99mTc-nanocolloid,
except the standard risks of the technical procedure: bleeding, vasovagal syncope
and local infection [6].
2.3.1.1 Lymphoscintigraphy and single-photon emission computed tomography
The disadvantages of radiocolloid are the lack of visual assessment and the need
for nuclear medicine procedures [30]. Lymphoscintigraphy and single-photon
emission computed tomography (SPECT) can obtain preoperative images of the
lymphatic drainage [38].
Lymphoscintigraphy obtains a flat static image with morphological information
of the lymphatic drainage of the injected radiocolloid [8, 41]. Lymphoscintigraphy
in EC offers varying results, depending on the injection method, with poorer
detection rates than the overall rates and poor correlation between the preoperative
findings and intraoperative detection [42, 43]. In the meta-analysis by Bodurtha-
Smith and Tanner [26] of 55 articles and 4915 included patients, preoperative
lymphoscintigraphy and the combined use of radiotracer with dye improved the
overall SLN detection rates (86 vs. 76%; p = 0.016 and 87 vs. 78%; p = 0.008,
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respectively); however, preoperative lymphoscintigraphy showed no benefit. An
explanation for the low resolution and correlation could be the proximity of the
injection site to the drainage, which can mask the SLN in flat images, and the
anatomical complexity of the pelvic area, which can cause confusion in the correct
anatomical description.
SPECT obtained a three-dimensional image with the fusion of the scintigraphic
image with that of the traditional scanner. SPECT provides image information on
the intensity of the scintigraphy and the precise anatomical location of the SLN(s)
by scanner [44]. In the study by Naaman et al. [45], SPECT achieved a topograph-
ical accuracy of 91%, detecting a higher number of SLNs (1.4 vs. 2.13 SLNs/patient).
Buda et al. achieved a detection rate of 50% and bilaterality of 39% for lymphoscin-
tigraphy. For SPECT, the authors achieved a detection rate of 91%, bilaterality of
53% and sensitivity and a negative predictive value of 100% [46]. Compared with
lymphoscintigraphy, the high sensitivity of SPECT seems to offer significant
improvement in detecting SLNs and in the anatomical location [47, 82].
2.4 Surgical detection
The surgical SLN detection techniques can be applied to open surgery, laparos-
copy and robot-assisted surgery [30], with overall detection rates of 60–100% [27].
Regarding the possibility of laparotomic detection, Mais et al. [48] used methylene
blue (MB) as tracer and observed a significant difference between the laparoscopic
pathway and laparotomy, with detection rates of 82 and 41%, respectively, although
with the same false negative rate (FNR).
The mean number of SLNs detected per patient is 2.9 (95% CI 2.5  3.3; range 1–
8) [26]. In terms of location, Abu-Rustum et al. [49] reported 89% of SLNs in the
territory between the external iliac, obturator and internal iliac areas, with 4% of
SLNs in the paraaortic area and 6% in the common iliac areas.
2.4.1 Radiocolloid
The gamma emissions of the radiocolloid can be tracked intraoperatively by a
portable gamma probe adapted to open surgery or laparoscopy [42]. The use of
laparoscopic gamma probe increases SLN identification guided anatomically by the
previous images of SPECT and lymphoscintigraphy [50]. The gamma probe emits a
signal proportional to the radioactivity uptake (analogue [counts per second] and
auditory), enabling the accurate localisation of the radiocolloid in the lymph node
station [38]. The activity will mark this lymph node regardless of whether is it
normal or pathological [38].
The radiocolloid is often used along with dye to optimise the detection rate and
visual assessment [30]. Studies with only radiotracer are therefore few, with a
detection rate in the range of 70–96% [6]. In the Detection Rate and Diagnostic
Accuracy of Sentinel-node Biopsy in Early Stage Endometrial Cancer (SENTI-
ENDO) multicentre study, the long protocol with an injection of radiocolloid
increased the detection rate of lymphoscintigraphy versus the short protocol (80.3
vs. 68.2%; p = 0.02). The paraaortic detection was more frequent in the long
protocol, with no intraoperative differences [40]. There was a weak correlation
between preoperative and intraoperative detection (k = 0.3) [40]. Other published
data indicate good detection rates of 82% [6] and bilaterality with both protocols.
While some authors use to perform another lymphoscintigraphy on the morning of
the surgery [43, 51], with similarly poor improvement and weak correlation [22].
Other authors have proposed injecting the radiocolloid intraoperatively after the
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induction of anaesthesia, omitting the preoperative imaging and identifying the
SLN directly with the gamma probe 30 min after the injection [36].
The disadvantages of this procedure include the high financial and staff costs,
the risk of radioactive exposure and patient discomfort during the preoperative
preparation. The advantages include the longer duration of the marking and fixa-
tion in the lymph node [15]. The technical limitations are related to the massive and
diffuse uptake by the tissue, the interference caused in the gamma probe (which
hinders the proper differentiation of the lymphatic tissue, especially in the
parametrium and obturator area) and the uptake by the reticuloendothelial system
(liver, spleen and bone marrow) [6, 27].
2.4.2 Dyes
2.4.2.1 Blue dye
The dye enables the visual identification of the SLN marked or not with the
radioisotope. Several dyes have been used: 1% isosulfan blue, 1% MB and 2.5%
patent blue. Isosulfan blue is a blue-green hygroscopic powder that is prepared by
diluting it in sterile water. MB was created in 1876 and is the first fully synthetic
drug used in medicine. Patent blue is a dark blue synthetic dye used as food
colouring, and its intensity fades quickly when exposed to sunlight [36].
The detection rates with only blue dye are lower (57–62%), with a bilaterality
of 56.1% (50–60%) [17, 52]. MB has lower diffusion but acceptable detection
rates (57.5%, range 45–92%) and bilaterality (42.4%, range 50–60%) [53].
Nevertheless, when SLNB is applied to other cancers, such as breast cancer, the
various dyes have shown accuracy and equivalence in SLN marking [36]. MB is
preferred due to the extensive experience with this dye and its better toxicity
profile. Due to the lower detection and given that the combination with 99mTc
or ICG results in higher detection rates, MB is not recommended for use in isolation
[21, 27].
After the blue dye is injected interstitially, it binds to the serum proteins and is
filtered to the lymphatic vessels passing to the SLN, which will be stained in blue in
approximately 5–10 min. This simple method requires no specific logistics, but the
SLN must be identified at the start of the procedure before the dye vanishes or is
displaced further along the lymphatic system and identifies a second nonsentinel
step [36].
MB is more economical and safer than isosulfan blue. The half-life is 5–6 h,
withmainly urinary and, to a lesser extent, biliary excretion. The recommendation is to
use 2–4ml of a 1% solution and to not takemore than 10–20min detecting the SLN due
to the diffusion of the dye through the lymphatic tissue. A number of authors have
estimated themean procedure time, with an interval of 13.4 6.2 min between the
injection and visualisation and a SLN excision time of 17.4 11.2 min [31].
Adverse effects related to the blue dye occur in 2% of cases [36]. The following
effects have been reported: severe allergic reactions and anaphylactic crises (0.7–
1.9%), thrombophlebitis at the injection site, tissue necrosis, haemolysis or para-
doxical methemoglobinemia and serotonin syndrome in patients undergoing treat-
ment with serotonin reuptake inhibitors [30, 54]. Patients and health professionals
should be advised of transient colouring of the urine and the possibility of interfer-
ence with pulse oximetry readings [36]. The use of the dye is contraindicated in
cases of hypersensitivity (MD induced allergic reaction and methemoglobinemia),
severe renal failure (dosage adjustments may be necessary as serum concentrations
are increased in patients with impaired renal function) and glucose-6-phosphate-
dehydrogenase deficiency (due to haemolytic anaemia when red blood cells are
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exposed to the chemical). The dye is not recommended for use during pregnancy or
breastfeeding because the dye’s safety has not been established.
2.4.2.2 Indocyanine green
Since the inclusion of fluorescence, the authors such as Holloway et al. [31] have
replaced the radiocolloid and achieved equally good results. ICG is a tricarbocyanine
dye with a short half-life of 3–4 min and hepatic excretion. ICG was developed by
Kodak in the 1950s for use in photography and was approved by the US Food and
Drug Administration in 1956 for IV administration [36]. The dye emits an intense
blue colour detectable in real time when excited by laser in the near-infrared
wavelength (range 750–900 nm, with an absorption peak at 800 nm) [6]. The high
avidity by lymphatic tissue enables a high detection rate and accuracy compared
with common tracers [4, 55, 56].
ICG has been used for years in laparoscopic and open surgery and in numerous
other specialties (cardiology, general surgery, ophthalmology, vascular surgery,
urology, etc.). The dye has recently been included in gynaecology. Lymph node
mapping by fluorescence with ICG was first described by Furukawa et al. in 2010 in
patients with cervical cancer. In 2012, Rossi et al. [57] applied ICG to 20 patients
with cervical cancer or EC who underwent robot-assisted laparoscopic detection,
achieving a detection rate of 85% and bilaterality of 60%.
The supposed benefits of this technology include high tissue penetration with
low autofluorescence [58]. ICG has been shown to be superior to blue dyes, partic-
ularly in patients with obesity [30]. Following an interstitial injection, ICG is
absorbed to the lymphatic system and travels quickly to the lymph nodes. ICG binds
to plasma proteins and is excreted by the liver [36]. The dye lacks significant
adverse effects. A single case of a severe allergic reaction after IV injection has been
reported (incidence rate of 0.05%) [59]. However, the dye is contraindicated for
use in patients with allergies to iodine [23, 55]. Nevertheless, given that iodine is a
chemical element and an essential component of the human body, a number of
authors have suggested the safety of using ICG in patients with iodine allergies,
given that a type I allergic reaction (antibody-mediated and responsible for ana-
phylactic shock) will not occur [36]. The use of ICG in pregnant patients has been
reported as safe [60].
To date, there has been no standard in the concentration and volume to be
injected. Rossi et al. [57], Jewell et al. [61] and Holloway et al. [62] established the
optimal ICG dose for detecting SLN at 1, 1.25 or 2.5 mg/mL in 4 mL [23]. Unlike
99mTc, ICG does not remain confined to a lymph node but rather diffuses rapidly
through the lymphatic tissue towards the second step lymph nodes without losing
intensity. It is therefore crucial to quickly start the search for the SLNs after the
administration of ICG, without delaying the start of detection by more than 10 min
[23], thereby reducing the risk of sampling too many lymph nodes [36], which
limits the technique beyond 25–30 min of the injection [63].
Erikson et al. [64] compared the isolated use of ICG and MB in 472 patients,
obtaining a higher detection rate (95 vs. 81%; p < 0.001) and bilaterality (85 vs.
54%; p < 0.001) with ICG. In 2015, How et al. [65] compared ICG, MB and 99mTc-
nanocolloid, obtaining a higher detection rate (86 vs. 71%; p = 0.005) and
bilaterality (65 vs. 43%; p = 0.002) with ICG than with MB and a similar rate (87 vs.
88%; p = 0.83) and bilaterality (65 vs. 71%; p = 0.36) to 99mTc. In 2016, Papadia
et al. [66] published the results of a retrospective, multicentre comparative study
between detection with the combined technique using radiocolloid and blue dye
versus radiocolloid and ICG. The overall detection rate was 97.3% for 99mTc-blue
and 96.9% for ICG (p = 0.547). The bilaterality was 84.1% with ICG and 73.5% with
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the blue dye; ICG was significantly superior (p = 0.007). In a series by Martinelli
et al. [19] of 202 cases using ICG plus 99mTc as tracer, there were no differences in
the detection rate (93.2%), and the bilateral detection was superior with ICG (72.8
vs. 53.3%; p = 0.0012). All of the authors (and many not mentioned here) agree that
ICG offers the highest detection rates comparable to those of the standard 99mTc-
blue technique but with superior bilaterality [11, 26].
ICG achieves greater diffusion; better visualisation; greater bilateral detection,
which translates into a lower risk of lymphadenectomy (61% with MB vs. 39% with
ICG; p < 0.001 [64]); a shorter surgical time and long-term financial savings and
can obviate the need for an injection of radiotracer [67]. It was initially stated that
ICG represented an increase in the number of resected SLNs, a finding that became
standard with experience in the technique [68]. Therefore, considering its good
toxicity profile, its ease of use and high effectiveness, ICG is the current tracer of
choice [69]. The main disadvantage of ICG is that the NIR detection equipment is
expensive, because it requires specific optical systems [70].
Advances in the fluorescence technique are ongoing. New NIR detection sys-
tems, such as the PINPOINT® Endoscopic Fluorescence Imaging System, specifi-
cally identify the uptake intensity with colour codes, such that the primary lymph
node is differentiated from the secondary nodes, preventing the excision of
nonlymphatic or canalicular tissue [71].
2.4.3 Combined method
The objective of the double injection method is to optimise the detection rate
and bilaterality, given that single dyes (mainly blue dyes) have lower detection
rates and bilaterality [27]. The recent systematic review by Cormier et al. [27]
achieved superior results with a combination of two tracers. Various combinations
have been applied.
2.4.3.1 Radiocolloid and blue dye
Results vary significantly; however, the conclusion is that a better detection rate
(81 vs. 57%; p = 0.01) and bilaterality (54 vs. 28%; p = 0.009) are achieved with the
combination than with the isolated application of each tracer [45]. The multicentre
prospective study by the AGO group with 590 patients obtained a better detection
rate applying the combined method of radiocolloid and patent blue dye (88.6 vs.
93.5%; p < 0.001). Other authors have achieved similarly improved surgical detec-
tion results by applying this double method, which has become established as the
most appropriate combination of tracers. The review by Ruscito et al. [69] com-
pared the detection by the combined technique (of 99mTc and MB) with ICG and
achieved superior bilaterality with ICG and a tendency to a higher overall detection
rate, without differences compared with the combined method.
2.4.3.2 Radiocolloid and ICG
How et al. [65] compared ICG and isosulfan blue with radiocolloid in a cervical
injection in 100 patients with EC. The detection rate (87 vs. 88%; p = 0.83) and
bilaterality (71 vs. 65%; p = 0.36) achieved with ICG and the radiocolloid were
comparable to the data obtained with only an injection of ICG. In the meta-analysis
by Lin et al. [72], the combined technique with 99mTc and ICG achieved a detection
rate of 92% and bilaterality of 86%, results comparable to those using only ICG
(91% and 78%, respectively).
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2.4.3.3 Blue dye and ICG
The prospective cohort study by Holloway et al. [31] combining blue dye with
ICG achieved a significant increase in the detection rate (87.8% with blue-ICG vs.
76% for blue alone), bilaterality (83.9% with blue-ICG vs. 40% for blue alone; p
< 0.001) and detection of lymphatic metastases (21.1% with blue-ICG vs. 13.5% for
blue alone; p = 0.056) versus the isolated injection of blue dye. In the study by
Jewell et al. [61], lymphatic mapping with ICG detected the SLN in 95% of cases,
with bilaterality of 79% and no statistically significant differences versus the com-
bined use with isosulfan blue (detection rate of 93%, p = 0.64; bilaterality of 77%,
p = 0.8). Other authors have reached the same conclusion as Jewell: the high
effectiveness in the identification with fluorescence is not increased by blue dye.
The combination therefore appears unnecessary, which would avoid an increased
risk of adverse effects [53].
2.4.4 Triple tracer
There are few published studies on this subject. How et al. [65] concluded that
the triple injection (blue dye, 99mTc and ICG) in the cervix (submucosa and stroma)
provided a detailed mapping of the lymphatic canals, from the parametrium and
presacral areas to the hypogastric vessels.
2.4.5 Paramagnetic tracer
New tracers are being applied. Recently, the Central-European SentiMAG
multicentre clinical trial compared the use of the standard tracer (99mTc-
nanocolloid and MB) with superparamagnetic iron oxide (SPIO) labelled
nanoparticles, marketed under the name Sienna+®. The preliminary results indi-
cated comparable detection rates of 97.3 versus 98% with the same number of SLNs
Characteristics 99mTc Blue ICG
Economic cost +  +
Technical complexity +  
Detection rate/
bilaterality
++ + +++
Comfort for the
patient
 + +
Need for specific
equipment
++
(Radiopharmaceutical/
lymphogammagraphy/SPECT–CT)
 +
(NIR detection
hardware)
Adverse Reactions 
(1–6/100.000)
++
(2%)

(<0.05%)
Lymphotropism ++ + +++
Duration marking 24 h/+++ 10–
20 min/+
20–30 min/++
The score was assigned according to the following gradation: () = absence of the characteristic or negative evaluation,
(+) = meets the characteristic or positive evaluation, (++) = complies being better; (+++) = it fulfils being superior.
99mTc = 99mTc-nanocolloid albumin; ICG = indocyanine green; NIR = near-infrared electromagnetic spectrum.
Reference source: Papadia et al. [36].
Table 2.
Characteristics of tracers.
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per patient and a tendency for the SPIO tracer to identify more metastatic SLNs,
although further research is needed [34].
Table 2 shows a comparison of the main characteristics of the most widely used
tracers.
3. Histological analysis
One of the main advantages that the SLN technique offers pathologists is the
ability to select and minimise the number of lymph nodes to study, which enables a
more exhaustive analysis and search for microscopic metastatic involvement.
3.1 Intraoperative value
Classically, the most widely used method for analysing SLNs has been the
intraoperative assessment with haematoxylin-eosin (H&E) of imprint cytology
performed in fresh samples and in frozen sections with rapid Diff-Quik staining.
Intraoperative examination is questionable due to its limitations, both in the
processing and in the results. Its success depends greatly on the collaboration
between the surgeon and pathologist [73]. An intraoperative assessment can only
examine a small portion of the SLN, has low sensitivity (56–67%) for the
intraoperative detection of metastases and has an FNR of 20–30%, which makes the
procedure inadequate and unsafe for the patient [74]. The results of Kim et al. [75]
indicate an intraoperative understaging of 24%. For Ballester et al. [76], the rate was
43.7%, with little assessment of low-volume metastases. Additionally, the frozen
sections distort the lymph node tissue, thereby precluding lymph node ultrastaging
[30] and precluding the detection of micrometastatic involvement in the case of
initially negative lymph nodes [74]. Currently, the guidelines of the National Com-
prehensive Cancer Network (NCCN) do not recommend the routine intraoperative
assessment of SLNs, except when there is high suspicion and a nonsentinel lymph
node [5]. However, other authors have emphasised the importance of
intraoperative study to avoid reoperations, especially in high-risk tumours [77].
3.2 Ultrastaging
Conventional histological examination of a nonsentinel lymph node involves a
single section along the lymph node’s major longitudinal axis and H&E staining,
with deeper levels or application of immunohistochemistry (IHC) at the patholo-
gist’s discretion [30].
Occasionally, the only evidence of extrauterine disease is the presence of metas-
tases in the SLN. Considering the poorer prognosis associated with the detection of
lymphatic metastases, a much more exhaustive analysis is justified [73, 78]. There-
fore, pathological assessment by the ultrastaging of the SLN is the most important
advance in the SLNB technique [79].
3.2.1 Histological ultrastaging and immunohistochemistry
The histological ultrastaging procedure includes a protocol for the series of
microscopic examinations of the SLN block fixed and imbedded in paraffin, with
the addition of the immunohistochemical analysis with cytokeratin measurement
(pan-cytokeratin kits AE1/AE2 or anti-CK19), thereby increasing the sensitivity
[79]. There are no formal evidence-based regimens for the pathology assessment of
SLNs in EC, which entails considerable variability among institutions and,
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therefore, debatable results [30]. The study by Euscher et al. [80] compared two
methods of ultrastaging by histological microsection, achieving increased detection
of metastatic SLN in 32% of patients, with a mean metastasis size of 0.24–0.38 mm,
with no differences in the detection rate by ultrastaging method. The algorithm
proposed by the MSKCC consists of an initial assessment by H&E and, if negative,
performing two adjacent 5-μm slices at two levels separated by 50 μm in the paraffin
block, applying H&E staining and pan-cytokeratins AE1/AE3 in each slice [81].
Holloway et al. [82] performed three slices per level, two of which were then
stained with H&E and one with AE1/AE3. Other authors have performed four levels
with six slices at 40 μm intervals (levels 1 and 2 with H&E and levels 3 and 4 with
AE1/AE3) or five levels (levels 1, 3 and 5 with H&E and 2 and 4 with AE1/AE3) [30]
(Figure 1).
Cytokeratin-19 (CK-19) is a protein of the intermediate filament responsible for
the structural integrity of epidermal epithelial cells, which in normal conditions is
not expressed in the lymphatic tissue and is expressed abnormally in more than
90% of cells by EC [83, 84]. CK-19 is a biomarker directly related to the capacity for
tumour dissemination in EC, with high sensitivity and a capacity for discriminating
between metastatic and nonmetastatic lymph nodes or areas of lymphovascular
invasion [84, 85].
Ultrastaging is a more complex procedure, requiring significant dedication, and
has the added risk of high intraobserver and interobserver variability. The diagnos-
tic categories of the American Joint Committee on Cancer (AJCC) are applied for
breast cancer, with the following classifications for SLN: negative (<200 individual
tumour cells or tumour cell aggregates <0.2 mm in size, including the presence of
isolated cytokeratin-positive tumour cells [ITC]), micrometastatic (size ≥0.2 and
<2 mm) (μM) or macrometastatic (>2 mm) (MM) [86]. The term low tumour
volume includes the ITC and μM categories.
The ultrastaging of SLN has improved the validity of the technique and detects
an additional 5–15%, with a high rate of low-volume lymph node disease (approxi-
mately 50% of patients with metastatic SLN), which would not be identified with
the conventional technique. Ultrastaging represents an overall mean increase of
25% (range, 10–60%) in detecting metastatic lymph nodes [79, 84].
Figure 1.
The SLN algorithm for surgical staging of endometrial cancer. Obtained from NCCN Guideline in Endometrial
Carcinoma, Version 4.2019: ‘Principles of evaluation and surgical staging when SLN mapping is used,
Figure 4: The SLN algorithm for surgical staging of endometrial cancer’. SLN = sentinel lymph node;
LND = lymph node dissection.
13
Role of Sentinel Node Biopsy in Endometrial Cancer
DOI: http://dx.doi.org/10.5772/intechopen.89949
Analysis by histological microsection and H&E detects 6.9% more patients with
metastatic SLN, while the inclusion of IHC provides an additional 4.5% (82.6% with
low tumour volume), which represents 12.6% of patients with metastatic SLN [81].
In the multicentre retrospective study by Raimond et al. [87] with 136 low-
intermediate risk cases, the detection of SLN and the ultrastaging analysis increased
the detection of metastatic lymph nodes threefold over lymphadenectomy (16.2 vs.
5.1%; p = 0.03); 11% of the cases were μM and 5.1% were MM, with an FNR of 0
(95% CI 0–1.6%). In the study, 6.1% of the metastatic SLN were detected by
histological microsection, and 10.1% were detected by IHC. All MM cases were
diagnosed by histological microsection, and 73.3% of the μM cases were diagnosed
by IHC readings. Thus, by applying ultrastaging, the SLNB restaged 50% of the
patients included in the study to an European Society of Medical Oncology (ESMO)
high risk (14.7% of the sample), thereby changing the adjuvant therapy compared
with women with negative or unassessed lymph nodes (p < 0.001). In the study by
Hagen et al. [88], 75% of patients with metastatic SLN were detected with histolog-
ical microsection and an additional 25% with IHC. For Desai et al. [89], 50% of the
metastatic SLNs were detected by IHC.
3.2.2. Molecular ultrastaging
The one-step nucleic acid amplification method (OSNA) is a validated technique
for breast cancer and enables a quantitative, systematic, automated, nonobserver-
dependent analysis for detecting lymph node metastases [73, 84]. The application of
this method always requires prior confirmation of CK-19 expression in the tumour
tissue [90, 91]. The application of radiocolloid or dye does not interfere with the
process. The number of mRNA copies of CK-19 corresponds to the size of the
metastatic foci present in the SLN [92], such that the results are visualised in four
separate categories: negative (<102 copies of mRNA/μL), ITC (102 to <2.5  102
copies of mRNA/μL), μM (≥2.5  102 to <5  103 copies mRNA/μL) and MM
(>5  103 copies mRNA/μL) [93].
The results of the Breast Complete Lymphadenectomy OSNA Study for
Enhanced Review-I (B-CLOSER-I) [94] indicate that histopathology (compared
with molecular detection) significantly underestimates the rate of metastases of
axillary lymph nodes.
Preliminary results of its application in EC indicate superior diagnostic accuracy
compared with conventional ultrastaging, although further research is needed. By
applying the OSNA method, the study by Nagai et al. [84] achieved sensitivity of
93.3%, specificity of 99.5%, a negative predictive value (NPV) of 99.5% and a
correlation of 99.1%. In the study by López-Ruiz et al. [85] of 34 patients with
chronic diseases and 94 analysed SLNs, the OSNA method detected a larger portion
of additional low tumour volume metastases, with diagnostic capacity (sensitivity
of 100%, specificity of 87.5%, accuracy of 88.3% and an FNR of 2.8%).
4. Approach and prognosis for metastatic sentinel nodes
The increase in detection of lymphatic metastases resulting from the introduc-
tion of ultrastaging is mainly at the expense of the detection of low tumour volume.
The NCCN guidelines [5] and the consensus of The Society of Gynecologic Oncol-
ogy (SGO) [30] recommend the study of SLNs by ultrastaging, indicating that the
significance of low-volume lymph node involvement is still uncertain and have not
established an optimal treatment approach [55, 95, 96].
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A number of authors have debated and hypothesised a different tumour biology
and therefore a different behaviour between tumours with MM and μM. For other
authors, μMmetastases appear early and are reflections of isolated metastases in
type 2 histology but would be metastases of late evolution in tumours with low
oncologic aggressiveness [97]. It has also been suggested that μMmetastases could
represent an intermediate state between negative lymph nodes and positive lymph
nodes for MM [98].
One of the aforementioned advantages of the SLNB technique in early stages is
avoiding the implementation of lymphadenectomy [87]. However, the therapeutic
benefit of completing the lymphadenectomy when faced with the finding of meta-
static SLN with low tumour volume remains unknown, and its systematic imple-
mentation is not justified [83, 98, 120]. The FIRES trial performed postoperative
radiological studies (with scanner or positron emission tomography-computed
tomography [PET-CT]). When the findings showed voluminous residual metasta-
ses, the proposed treatment was surgical cytoreduction or a change in the adjuvant
radiation therapy (RT) to include the paraaortic area [74].
In recent years, research has been conducted on the possible influence of adju-
vant therapy and the prognosis for patients with low-volume lymphatic metastases
[99]. There is still no evidence from prospective randomised studies on cases with
detected low-volume metastatic tumours, resulting in heterogeneity among the
published studies [56]. Moreover, it is important to determine the benefit provided
to these patients by combining CT and/or adjuvant RT, considering the scarce
survival benefit obtained. The study by Plante et al. [100] analysed the impact of
adjuvant therapy on survival. Thirty-five percent of the patients with ITC in the
SLN underwent CT and external beam RT, 32% only underwent external beam RT
or vaginal brachytherapy and 32% underwent follow-up. The overall survival at
3 years in the group with ITC was 95.5%, with no differences compared with the
patients without metastatic lymph nodes or with μM in the SLN (87.6 and 85.5%,
respectively). However, the low tumour volume SLN was superior to the SLN with
MM (58.5%; p < 0.001).
Significant differences have not been observed between the prognosis of
patients with only SLN excision versus those with lymphadenectomy (disease-free
survival [DFS] at 3 years of 94.9 vs. 96.8%; p = 0.35). However, it has been observed
that the patient group with metastatic SLN increases the portion of adjuvant ther-
apy received (27.1 vs. 10.8%; p < 0.001) [101]. In the retrospective series by
Raimond et al. [87], neither the absence of metastases in SLN, the detection of
metastatic SLN nor the presence of μM in the SLN represented an improvement in
DFS ([hazard ratio (HR), 0.89; 95% CI 0.42–1.90; p = 0.77], [HR, 0.82; 95% CI
0.18–3.64; p = 0.8] and [HR, 0.46; 95% CI 0.03–7.42; p = 0.59], respectively). When
comparing negative lymphadenectomy with the detection of lymphatic metastases,
there were no differences in DFS (HR, 1.13; 95% CI 0.34–3.76; p = 0.84) or overall
survival (HR, 1.29; 95% CI 0.30–5.59; p = 0.73).
Yabushita et al. [92] showed that the detection of μM and SLN was an indepen-
dent factor for recurrence in early stages of EC. Kim et al. [75] measured a tendency
to late distant metastasis when the SLN was metastatic for μM. For Todo et al. [97],
ITCs in the paraaortic area were not associated with a greater risk of
nonlymphogenic or extrapelvic recurrence. For Kim et al. [75], these ITCs did not
represent increased relapses. In the study by Erkanli et al. [102], DFS and overall
survival were significantly lower in patients with μM (p < 0.05), while the presence
of ITCs appeared to have no effect on survival. In another study by Todo et al.
[103], the presence of low tumour volume was an independent factor for
extrapelvic relapse (RR, 17.9), with 20% lower survival (overall survival of 71.4 vs.
91.9% and DFS of 55.6 vs. 84%; p = 0.074) and a tendency towards late relapse
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Authors/trial Journal, year Injection Tracer N SLN/
case
DR BL Se NPN FNR FN
localization
DR
PAO
(%)
Ballester et al.
(SENTIENDO) [104]
Lancet Oncol. 2011 Cervical 99mTc + Blue 125 2 89 69 84 97 15 PAO1 5
Khoury-Collado et al. [78] Gynecol Oncol. 2011 Cervical7 99mTc w/o Blue 266 3 84 67 78 93
Barlin et al. [3]2 Gynecol Oncol. 2012 Cervical Blue 498 3 81 51 98 99.8 1.9 PAO
How et al. [105] Gynecol Oncol. 2012 Cervical 99mTc + Blue 100 2 92 72 89 99 1 PAO 16.3
Raimond et al. [87] Gynecol Oncol. 2014 Cervical 99mTc + Blue 304 2.5 87.2 65.4 03
Touhami et al. [77] Gynecol Oncol. 2015 Cervical 99mTc + Blue 268 2 94 73.5 97.2 99.4 0.64
Hagen et al. [88] Gynecol Oncol. 2016 Cervical ICG 108 4 96 78 5.8
Ehrisman et al. [106] Gynecol Oncol
Reports. 2016
Cervical ICG or MB 36 2 83 56 92.3 7.75 3
Holloway et al. [82] Gynecol Oncol. 2016 Cervical ICG + blue 780 3 98.3 80.7 2.8 9
Rossi et al. (FIRES) [74] Lancet Oncol. 2017 Cervical ICG 385 86 97.2 99.6 2.7 1
Plante et al. [100] Gynecol Oncol. 2017 Cervical 99mTc + Blue or ICG 519 2.2 98.4 99.7
Soliman et al. [107] Gynecol Oncol. 2017 Cervical 99mTc + Blue or
Blue or ICG
101 2 89 58 95 98.6 56 2
P
(μ  ) 3490 2.3  0.9 89  5.5 67  9.6 92  7.6 97  2.9 4.2  4.5 6  5.7
Bodurtha-Smith et al.
Meta-analysis [26]
Am. J Obstet &
Gynecol. 2016
Cervical or
uterine corpus
Dye (MB or ICG)
w/o 99mTc
4915 2.9 81 50 96 99.7 17
Lin et al. Meta-analysis7 [72] Oncotarget. 2017 Various Various 2236 — 83 56 91
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The results of 13 methodologically comparable studies are cited; studies include more than a hundred of cases, except for the one of Ehrisman et al. [106] because it is one of the recently published studies
that includes patients with high-risk endometrial cancer. The studies include cases with all histological type and two papers only high-risk cases, the one mentioned by Ehrisman et al. [106] and Soliman et al.
[107] The average of the collected variables is estimated. Results of two meta-analyses, which have not been added in the estimation, are attached to the possibility that the previously mentioned studies were
already included in their data. The word “Various” indicates that various injection methods or tracer combinations were collected. The blank box indicates that this information has not been mentioned in the
article.
N = patients included; SLN = sentinel lymph node; DR = detection rate; BL = bilaterality; Se = sensibility; NPV = negative predictive value; FNR = false negative rate; FN = false negative; (+) = metastasis; w/o
= with or without; (%) = proportion; Σ = summation; (μ  σ) = mean  standard deviation; 99mTc = 99mTc-nanocolloid albumin; MB = methylene blue; ICG = indocyanine green; PAO = paraaortic.
1All three FNR cases had nonendometrioid histology, one with paraaortic positive drainage. There were no cases of isolated paraaortic drainage.
2The data are reflected after application of the MSKCC proposed surgical algorithm. Without applying the algorithm: Se of 85.1%, VPN of 98.1% and FNR of 14.9%. One FNR case with isolated paraaortic
metastasis.
3The estimation of the FNR is performed from the total of negative lymphadenectomies; it does not include negative SLN and positive lymphadenectomy, in which case it would be a FNR of 9.1%.
4The predictive capacity is estimated only based on cases with SLN detected bilaterally.
5Null FNR with Se and NPV of 100% after the retrospective application of the MSKCC algorithm.
6The FNR would be 4.3% after adjusting by MSKCC algorithm.
7Surgical detection with dual technique: radiotracer and dye. ICG increases the overall detection rate to 93% and bilaterality of 78%. Cervical injection increases Se to 93% and detection rate to 86%.
Table 3.
Analysis of recent studies: Detection rate, predictive capacity, false negative rate and paraaortic drainage of the sentinel node.
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Authors/trial Journal year Injection Tracer N SLN+ Single SLN+ LTV ITC μM MM
(%)
Ballester et al. (SENTIENDO) [104] Lancet Oncol. 2011 Cervical 99mTc + Blue 125 17 8.5 1 7.5 8.5
Khoury-Collado et al. [78] Gynecol Oncol. 2011 Cervical (7) 99mTc w/o Blue 266 12 3 9
Barlin et al. [3] Gynecol Oncol. 2012 Cervical Blue 498 10
How et al. [105] Gynecol Oncol. 2012 Cervical 99mTc + Blue 100 11 44
Raimond et al. [87] Gynecol Oncol. 2014 Cervical 99mTc + Blue 304 16.2 11 11 5.1
St. Clair et al. [108] Annals of Surg Oncol. 2015 Cervical ICG o Blue 844 10.8 5.3 2.7 2.6 5.6
Touhami et al. [77] Gynecol Oncol. 2015 Cervical 99mTc + Blue 268 16 4.5 2.6 8.9
Hagen et al. [88] Gynecol Oncol. 2016 Cervical ICG 108 16
Holloway et al. [82] Gynecol Oncol. 2016 Cervical ICG + Blue 780 15.8 51.4 5.4 2.2 3.2 10.4
Ehrisman et al. [106] Gynecol Oncol Reports. 2016 Cervical ICG o MB 36 15
Rossi et al. (FIRES) [74] The Lancet Oncol. 2017 Cervical ICG 385 12
Plante et al. [100] Gynecol Oncol. 2017 Cervical 99mTc + Blue o ICG 519 16.4 8.1 6 2.1 8.3
Soliman et al. [107] Gynecol Oncol. 2017 Cervical 99mTC + Azul or Blue or ICG 101 23 40 9.9 2.5 7.4 13.1
P
(μ  σ) 4334 14.7  3.5 45.1  5.8 7.3  2.8 3.1  1.8 5.2  3.4 8.6  2.5
The results of 13 methodologically comparable studies are cited; studies include more than a hundred of cases, except for the one of Ehrisman et al. [106] because it is one of the recently published studies that
includes patients with high-risk endometrial cancer. The studies include cases with all histological type and two papers only high-risk cases, the one mentioned by Ehrisman et al. [106] and Soliman et al. [107].
The average of the collected variables is estimated. The blank box indicates that this information has not been mentioned in the article.
N = patients included; SLN = sentinel lymph node; DR = detection rate; (+) = metastasis; LTV = low tumour volume (includes ITC and μM); ITC = isolated tumour cells; μM = micrometastasis;
MM = macrometastasis; w/o = with or without; (%) = proportion; Σ = summation; (μ  σ) = mean  standard deviation; 99mTc = 99mTc-nanocolloid albumin; MB = methylene blue; ICG = indocyanine
green.
Table 4.
Analysis of recent studies: proportion of patients with metastatic sentinel node, proportion of single metastatic sentinel node and distribution by type of metastases detected.
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(49 vs. 16.5 months; p = 0.066) compared with the patient group without lymphatic
metastasis. The conclusion of these studies is that the presence of μM can represent
a prognostic biomarker in terms of survival, but whether the presence of ITCs
should be used as such, regardless of other clinical-pathological risk factors, is still
unknown [30] (Tables 3 and 4).
5. Recommendations for the clinical application of selective sentinel
node biopsy
The published results of SLNB in EC have shown good diagnostic performance.
SNLB is a promising and safe technique from the oncological point of view [10].
Given the mixed results, which have failed to show a therapeutic benefit [9], and
the lack of long-term results [5], an appropriate interpretation is recommended
[4, 29], considering SNLB a technique under study [78].
As with lymphadenectomy and adjuvant therapy, SNLB can be safely omitted for
low-risk patients (endometrioid histology: IA G1, IA G2) [9, 55]. For intermediate-
risk (endometrioid histology: IA G3, IB G1, IB G2) patients, SNLB has not shown a
clear benefit in survival when performing systematic lymphadenectomy. This group
does, however, have a greater risk of lymphatic involvement and typically undergo
adjuvant therapy. SLNB in both patient groups has been shown to detect 2–3 times
more cases of metastatic EC than lymphadenectomy, without changing the disease
prognosis [87, 109]. These results justify extending the technique to low to interme-
diate risk, with the recommendation of including it in an algorithm or surgical
protocol that includes the implementation when faced with failure of the technique.
The potential benefit of detecting metastatic SLN in low-risk patients is however
diluted by the low incidence of cases and the high proportion of low tumour volume.
It appears we need to clarify the role of SLNB and the effect of low tumour volume,
which is more frequently detected in this group [87, 109].
Two randomised clinical trials did not show that lymphadenectomy changed
overall survival or relapse rates in high-risk patients [110–112], although retrospec-
tive series did show this change [113, 114]. The implementation of pelvic and
paraaortic lymphadenectomy has been systematised due to the higher rate of lym-
phatic metastases and poorer prognosis associated with their detection. In contrast,
sceptics of lymphadenectomy state that routine nodal assessment of high-risk
patients rarely changes the recommendations for adjuvant therapy. EC (especially
in high-risk cases) is not just a disease confined to the pelvis [50]. Patients with
high-risk EC have a higher probability of recurrence and recidivism with or without
detection of lymphatic metastases and should undergo systemic therapy regardless
of the nodal state [115]. Nevertheless, published results on high-risk patients have
shown no differences compared with those expected from studies that also include
low- to intermediate-risk cases, with the same incidence of paraaortic metastasis
estimated by lymphadenectomy. Survival data have shown no differences [30],
which would assume that the benefit of SNLB in high-risk patients would be
equivalent to lymphadenectomy alone [106, 107].
In terms of applying SLNB to high-risk patients, the greatest debate concerns
paraaortic drainage, with a greater proportion of undetected metastatic paraaortic
nonsentinel lymph nodes. A study by Naoura et al. [116] analysed 180 patients and
achieved a much higher FNR in the high-risk group (2.3 vs. 20%; p < 0.001). In this
study, it was much more likely that the high-risk subtype (7 vs. 28%; p = 0.03) and
the nonendometrioid type (8 vs. 29%; p = 0.02) were poorly assessed.
The FIRES study [74] on 385 patients represents the largest prospective series to
date and included low and high-risk patients, achieving a sensitivity of 97.2% and
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an NPV of 99.6%. Fifty percent of detected metastatic SLNs were in patients with
low-risk EC, the most incidental group. Only 1% were isolated paraaortic metasta-
ses, with an FNR of 2.7%. Barlin et al. [3] and the FIRES study concluded that a
pelvically located SLN could be sufficient for directing the treatment [74].
In light of these results and lacking a therapeutic benefit for lymphadenectomy,
the current guidelines recommend that only pelvic SLNs should be determined (and
with caution) in this high-risk patient group [5, 30]. Until there is better evidence,
the recommendation is to perform systematic lymphadenectomy adding SLNB,
which a number of authors have labelled as ‘high-precision lymphadenectomy’.
To decrease the number of faults in the technique and the risk of underdiagnosis
in high-risk cases, several research groups have performed PET-CT, excluding cases
with peritoneal or lymphatic uptake [117]. Other authors have included postoperative
scans or PET in cases in which the paraaortic lymphadenectomy was not completed
[30]. Another option for managing high-risk patients includes implementing a com-
bined injection pathway, ensuring both pelvic and paraaortic drainage.
The Selective Targeting of Adjuvant Therapy in Endometrial Cancer (STATEC)
in the United Kingdom [30] and the Evaluation of Sentinel Node Policy in Early
Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence
(SENTIRAD) in France are two studies currently underway on high-risk patients,
comparing the effect of SLNB versus systematic lymphadenectomy (bilateral pelvic
and paraaortic) in high-risk EC in initial clinical stages. The STATEC study com-
pares SLNB versus lymphadenectomy with the patient as the same control. The
SENTIRAD study randomised patients to SLNB or lymphadenectomy, following an
algorithm that performs bilateral pelvic and paraaortic lymphadenectomy when
faced with a failure in detection or unilateral detection.
In 2014, the NCCN clinical guidelines assessed the technique as an acceptable
alternative to systematic lymphadenectomy in selected cases [36]. In the latest
edition, NCCN [5] (v.3.2019) accepted the technique as category 2A (based on
lower level evidence with uniform consensus by the expert panel that the procedure
was appropriate) and established a number of recommendations:
• SLN mapping may be considered
• The application of SLN mapping is appropriate for low intermediate-risk
patients or those who do not tolerate standard lymphadenectomy.
• Recent evidence indicates that sentinel node mapping may also be used in
high-risk histologies (serous carcinoma, clear cell carcinoma, carcinosarcoma).
• Cervical injection (superficial and optional deep) is a useful and valid option.
• The use of a radiocolloid with blue dye is recommended. The usefulness of ICG
is admitted if NIR detection equipment is available.
• The key point in the normalisation of the technique is adherence to a surgical
protocol.
• SLNB should be performed in institutions with experience in this procedure.
The technique requires proper methodology and demands good anatomical
knowledge and surgical ability. The MSKCC group recommends performing
SLNB in centres with experience in endoscopic surgery and with an experience
of at least 30 supervised cases during the learning process, with a specialised
team that enables close collaboration between the surgeon and pathologist [32].
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In the study by Papadia et al. [118], the implementation of at least 20
procedures decreased the number of SLNs obtained without compromising the
FNR, improving the accuracy of the technique.
• The histological analysis should be performed by ultrastaging. Although the
implication and proper management of low tumour volume are not known, its
detection has a potential effect on staging.
• Lymphatic mapping implementation is contraindicated in uterine sarcoma.
Recently, the SGO published a first consensus on the application of SLNB in EC
[30], which concluded with the following recommendations:
• Lymphatic mapping with cervical injection accurately predicts the detection of
lymphatic metastasis, with an FNR <5%. In institutions with higher FNRs, the
implementation of lymphadenectomy should be maintained (if it was
previously indicated) until an FNR <5% has been ensured. Similarly, the SGO
suggests adopting the indications of the American Society of Clinical Oncology
applied to SLNB in breast cancer, such that lymphadenectomy is completed
after SLNB in the first 20–30 cases. For low-risk patients, the recommendation
is to increase the number of supervised cases during the learning process, given
the lower risk of detecting lymphatic metastases [36, 119].
• The injection of radiocolloid and dye is acceptable. If ICG is available, it should
be used instead.
• For patients with low- to intermediate-grade type I EC and tumour
confinement to the uterus, lymphadenectomy can be skipped, performing only
the SLNB.
• Although SLNB has been shown to increase the detection of lymphatic
metastases, patients should be informed of the potential risk of undetected
occult disease.
• The main demonstrated usefulness of SLNB is in detecting pelvic metastasis.
The decision to perform paraaortic lymphadenectomy is at the surgical team’s
discretion, considering the patient’s clinicopathological characteristics.
• Ultrastaging is recommended in the analysis of the SLN, although its
involvement in detecting ITC requires more research.
• The application of SLNB to high-risk patients (type 1 G3 and type 2 histology)
following the NCCN algorithm is feasible and has had good published results
[30]. The combination of pelvic and paraaortic lymphadenectomy is
reasonable until more safety and efficacy data for SLNB are available.
Abbreviations
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CK19 cytokeratin 19
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HR hazard ratio
ICG indocyanine green
IHQ Immunohistochemistry
ITC isolated tumour cells
MB methylene blue
MM macrometastases
NPV negative predictive value
OSNA one-step nuclear acid amplification
PET-CT positron emission tomography-computed tomography
RR relative risk
RT radiotherapy (includes EBRT y vaginal-cuff brachytherapy)
Se sensibility
SLN sentinel lymph node
SLNB sentinel lymph node biopsy
Sp specificity
SPECT single photon emission computed tomography
vs. versus
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μ meanP
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